Non Hodgkin Lymphoma Clinical Trial

The clonoSEQ® Watch Registry

Summary

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

View Full Description

Full Description

Data show that detection of MRD may be important to guide treatment decisions in ALL, MM, CLL, and NHL. However, there remains a lack of real-world evidence for making therapeutic decisions based upon MRD status. This study is designed to understand when in a patient's treatment continuum the assay is used and how clonoSEQ MRD data impact the treatment decisions made by investigators.

All patients enrolled in the study will be followed for at least 2 yrs. Demographic data and disease status will be captured at study enrollment. Patients must be >/= 18 yrs of age and able to sign informed consent. A given patient is eligible to enroll in the study if the treating physician has made the decision to use the clonoSEQ assay as part of that patient's routine cancer care. Reasons for placing a clonoSEQ order and subsequent decisions made as a result of MRD data will be tracked. Patient treatment will also be tracked over the course of the study in order to understand how clonoSEQ use is incorporated into current treatment regimens.

Participating centers will include sites that actively use clonoSEQ to manage their patients with lymphoid malignancies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must be able to provide written informed consent
A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
Age ≥ 18 years;

Documented hematologic malignancy (any of the below):

MM
ALL (B and T-cell subtypes)
B-cell NHL (all sub types)
CLL
Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the study:

Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol
A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

528

Study ID:

NCT04545333

Recruitment Status:

Recruiting

Sponsor:

Adaptive Biotechnologies

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 15 Locations for this study

See Locations Near You

Stanford Hospital
Stanford California, 94305, United States More Info
Janet McDowell
Contact
Lori Muffly, MD
Principal Investigator
University of Colorado - Anschutz Medical Campus
Aurora Colorado, 80045, United States More Info
Derek Schatz
Contact
Tomer Mark, MD
Principal Investigator
Georgetown University
Washington District of Columbia, 20007, United States More Info
Catherine Lai
Contact
Catherine Lai
Principal Investigator
Holy Cross Hospital
Fort Lauderdale Florida, 33308, United States More Info
Eileen Georgi
Contact
Georges Azzi
Principal Investigator
Edward H. Kaplan MD & Associates
Skokie Illinois, 60076, United States More Info
Marlon Kleinman
Contact
Marlon Kleinman
Principal Investigator
Hematology Oncology Clinic
Baton Rouge Louisiana, 70809, United States More Info
Michael Castine
Contact
Michael Castine
Principal Investigator
American Oncology Partners of Maryland
Bethesda Maryland, 20817, United States More Info
Bruce Cheson
Contact
Bruce Cheson
Principal Investigator
Washington University
Saint Louis Missouri, 63130, United States More Info
Mark Fiala
Contact
Ravi Vij, MD
Principal Investigator
Novant Health
Charlotte North Carolina, 28204, United States More Info
Alan Skarbnik
Contact
Alan Skarbnik
Principal Investigator
Oregon Health & Science University, Knight Cancer Institute
Portland Oregon, 97239, United States More Info
Tara Lundberg Williams
Contact
Jessica Leonard, MD
Principal Investigator
Hospital of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Kristy Walsh
Contact
Jakub Svoboda, MD
Principal Investigator
Bon Secours St Francis
Greenville South Carolina, 29607, United States More Info
Amy Adams
Contact
Howland Crosswell, MD
Principal Investigator
University of Washington, Seattle Cancer Care Alliance
Seattle Washington, 98102, United States More Info
Peter Wilcox
Contact
Andrew Cowan, MD
Principal Investigator
Swedish Cancer Institute
Seattle Washington, 98104, United States More Info
Krish Patel
Contact
Krish Patel
Principal Investigator
Northwest Medical Specialists
Tacoma Washington, 98405, United States More Info
Emily Kerry
Contact
Swathi Namburi, MD
Principal Investigator
Northwest Medical Specialties
Tacoma Washington, 98405, United States More Info
Swathi Namburi
Contact
Swathi Namburi
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

528

Study ID:

NCT04545333

Recruitment Status:

Recruiting

Sponsor:


Adaptive Biotechnologies

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.